Treatment of BK virus-associated nephropathy with Cidofovir in renal transplantation.
BK virus-associated nephropathy (BKVN) has become recognized as an important cause of allograft dysfunction among transplant recipients. Despite reduction in immunosuppression, 30%-40% of recipients progress to allograft loss. Cidofovir is an antiviral agent that has been proposed for treatment of BKVN. We describe the clinical course, renal function, and blood viral measurement in 6 renal transplant recipients with BKVN who were treated with low doses of cidofovir. Administration of cidofovir was associated with clearance of BK virus DNA from blood and stabilization of renal function in 5 cases. These data suggest that cidofovir may be useful as adjuvant therapy for BKVN.
Cabello
V
V
Nephrology Service, Renal Transplant Unit, Hospital Virgen del Rocio, Seville, Spain. vicacha@gmail.com
Margarit
N
N
Díaz Pedrero
M
M
Bernal
G
G
Pereira
P
P
Gentil
M A
MA
D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D001739:BK Virus / Q000187:drug effects*; D000077404:Cidofovir; D003596:Cytosine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004279:DNA, Viral / Q000097:blood; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000601:surgery; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D063065:Organophosphonates / Q000627:therapeutic use*; D016133:Polymerase Chain Reaction; D027601:Polyomavirus Infections / Q000188:drug therapy* / Q000473:pathology; D014412:Tumor Virus Infections / Q000188:drug therapy* / Q000473:pathology
D000998:Antiviral Agents; D004279:DNA, Viral; D063065:Organophosphonates; D003596:Cytosine; D000077404:Cidofovir